U.S. stock alert: Inhibrx surged on November 19 as Ozekibart plus Ewing sarcoma showed an ORR of 62.7%
Bitget异动解读2026/11/19 15:21Inhibrx Soars on November 19: An Analysis
Keywords: Ozekibart, Ewing sarcoma, ORR 62.7%
1. On November 17, 2026, Inhibrx announced the latest clinical data from the phase 1/2 expansion study of ozekibart INBRX-109 in combination with irinotecan and temozolomide for the treatment of relapsed/refractory Ewing sarcoma. The objective response rate (ORR) reached 62.7%, and the disease control rate (DCR) was 86.3%. Durable responses were observed in patients who had received multiple prior lines of therapy. This data will be presented as a poster at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting.
2. The company is a clinical-stage biopharmaceutical enterprise focused on developing novel biologic therapeutic candidates. Ozekibart is a tetravalent death receptor 5 (DR5) agonist, which is also being advanced for indications such as chondrosarcoma besides Ewing sarcoma. The biologics license application (BLA) for chondrosarcoma is currently under FDA review.
(Disclaimer: This content is summarized from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US President Donald Trump’s Company May Face $883.5 Million in Debt! Will Bitcoins Be Sold?

US Stocks Movement: PACS plunged on November 19 due to overvaluation and pressure on discounted cash flow